Abstracts Archive - Page 372 of 2425 - ACR Meeting Abstracts

Abstract Number: 1304 • ACR Convergence 2022
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
Thomas Ambrosi¹, Mathew Murphy¹, Charles KF Chan¹ and Nancy Lane², ¹Stanford University, Stanford, CA, ²University of California Davis, Hillsborough, CA
Background/Purpose: Glucocorticoid (GC) induced osteoporosis remains a significant health issue. While GCs are known to reduce bone formation and bone mass, patients treated with GCs…
Abstract Number: 1305 • ACR Convergence 2022
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Joshua Novack¹, Gregory Chang², Stephen Honig¹, Anmol Monga², Xiaoliu Zhang³, Punam Saha³, Dimitri Martel², Peter Izmirly⁴, H Michael Belmont⁵, Jill Buyon⁴ and Amit Saxena⁵, ¹NYU Langone Health Department of Medicine, New York, NY, ²NYU Langone Health Department of Radiology, New York, NY, ³University of Iowa Departments of Radiology and Electrical and Computer Engineering, Iowa City, IA, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Fractures in patients with systemic lupus erythematosus (SLE) are more common than age and sex matched controls. Fracture risk is traditionally assessed by dual-energy…
Abstract Number: 1308 • ACR Convergence 2022
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Romesa Hassan¹, Bashar Alzghoul², Shiva Arami¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Christian Ascoli¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
Abstract Number: 1307 • ACR Convergence 2022
Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
Nancy Lane¹, Donald Betah², Cynthia Deignan², Mary Oates², Zhenxun Wang², Jen Timoshenko³, Aliya Khan⁴ and Neil Binkley⁵, ¹University of California Davis, Hillsborough, CA, ²Amgen, Inc., Thousand Oaks, CA, ³UCB Pharma, Slough, United Kingdom, ⁴McMaster University, Oakville, ON, Canada, ⁵University of Wisconsin, Madison, WI
Background/Purpose: Osteoarthritis (OA) and osteoporosis (OP) often occur concomitantly in the elderly. The relationship between OA and OP is complex, with increased fracture risk reported…
Abstract Number: 1286 • ACR Convergence 2022
Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center
Joad Eseddi¹, DeAnne Carmichael², Shannon Wishin³ and Puneet Bajaj², ¹UT Southwestern School of Medicine, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Centre, Dallas, TX
Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
Abstract Number: 1297 • ACR Convergence 2022
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Abdulaziz el Mutairi¹, Amanda Steiman² and Earl Silverman³, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²Sinai Health System, Toronto, ON, Canada, ³The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease affecting 1 in 1000 individuals, of whom 20% develop the disease in childhood. Childhood-onset…
Abstract Number: 1312 • ACR Convergence 2022
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Leny Pearman⁴, jake Mathew⁴, Yamei Wang⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Waltham, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
Abstract Number: 1310 • ACR Convergence 2022
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
Bjoern Buehring¹, David Kiefer², Celina Mueller², Roshnak Parvaee², Marianti Ifanti², Ioana Andreica³, Timm Westhoff⁴, Rainer Wirth⁴, Xenofon Baraliakos⁵, Nina Babel⁴ and Juergen Braun², ¹Bergisches Rheuma-Zentrum, Wuppertal, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMD) have an increased fracture risk (FxR). Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory disease characterized by…
Abstract Number: 1306 • ACR Convergence 2022
Improving Osteoporosis Screening in Individuals of Color
Megan Brochu¹, Kristofer Marcus¹, Sarah Latorre¹, Francis Wanjau¹, Arvin Garg², Eric Alper², Rulan Lyu¹, Tracey Wilkie¹ and Jonathan Cheah³, ¹UMass Memorial Health, Worcester, MA, ²UMass Memorial Health, UMass Chan Medical School, Worcester, MA, ³UMass Chan Medical School, Worcester, MA
Background/Purpose: Osteoporosis, including the clinical event of fragility fracture is an ever-increasing public health burden. Effective screening techniques and well as therapies to reduce future…
Abstract Number: 1257 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, F. Javier Narváez⁴, Vicente Aldasoro⁵, Olga Maiz⁶, Rafael Melero⁷, Juan Ignacio Villa Blanco⁸, Paloma Vela-Casampere⁹, Susana Romero Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galíndez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesus Fernandez¹⁵, Carles Galisteo¹⁶, Ivan Ferraz Amaro¹⁷, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁸, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Sierrallana Hospital, Torrelavega, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Complexo Hospitalario Universitario, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁵Hospital de La Coruña, La Coruña, Spain, ¹⁶Hospital Parc Tauli,, Sabadel, Spain, ¹⁷Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁸Hospital de Sierrallana, Torrelavega, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Positron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in…
Abstract Number: 1289 • ACR Convergence 2022
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Suguni Aushadhi Loku Galappaththy¹ and Nicole Fearing², ¹University of Missouri Kansas City, Kansas City, MO, ²HCA Menorah Medical Center, Overland Park, KS
Background/Purpose: As the number of bariatric procedures increases, surgeons will encounter more patients on long-term immunosuppressive medications that may increase post-operative complications. Currently, there are…
Abstract Number: 1302 • ACR Convergence 2022
Assessment of the Transition of Care from Pediatric to Adult Rheumatology in a Tertiary Center
Serdal Ugurlu¹, Ali Yagiz Ayla¹, Helin Idil Besiroglu², Feyza Nur Azman¹, Bugra Egeli³, Hatice Eren¹, Ibrahim Durucan², Arif Alkan², Sila Ozturk¹, Sercan Ergun¹, Amra Adrovic Yildiz⁴, Kenan Barut⁵, Fatih Haslak¹, Sezgin Sahin¹, Mehmet YILDIZ¹, Huri Ozdogan⁶ and Ozgur Kasapcopur⁷, ¹Istanbul University-Cerrahpaşa, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, ³Children's Hospital of Los Angeles, Los Angeles, CA, ⁴School of Medicine, KOC University, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁶Istanbul University-Cerrahpaşa Medical Faculty Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey
Background/Purpose: Taking the responsibility for their own health should be an important goal for the patients in the health care transition process. The Transition Readiness…
Abstract Number: 1266 • ACR Convergence 2022
Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
Takehisa Ogura¹, Takaharu Katagiri², Yuto Takakura³, Chihiro Imaizumi⁴ and Hideto Kameda⁴, ¹Toho university, Meguro-ku, Japan, ²Toho University School of Medicine (Ohashi Medical Center), Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Toho University, Setagayaku, Japan, ⁴Toho University, Tokyo, Japan
Background/Purpose: Ultrasonography (US) has been suggested to be useful in predicting flare in patients with rheumatoid arthritis (RA) after discontinuation of biological disease-modifying antirheumatic drugs…
Abstract Number: 1298 • ACR Convergence 2022
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
Catherine Bingham¹, Julia Harris², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Kerry Ferraro⁶, Tingting Qiu⁷, Jon Burnham⁸, Michelle Batthish⁹, Beth Gottlieb¹⁰, Daniel Lovell⁷, Ronald Laxer¹¹, Tzielan Lee¹², Danielle Bullock¹³, Charles H Spencer¹⁴, Jennifer Weiss¹⁵, Melissa Hazen¹⁶, Edward Oberle¹⁷, Melissa Mannion¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Danielle Fair²¹, Mary Toth²², Kendra Wiegand⁷ and Esi Morgan²³, ¹Penn State Children's Hospital, Hershey, PA, ²Children's Mercy Kansas City, Overland Park, KS, ³Atrium Health Levine Children's, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, ⁶Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹²Stanford University School of Medicine, Palo Alto, CA, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁵Hackensack University Medical Center, Hackensack, NJ, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ²²Nemours Foundation, Orlando, FL, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic…
Abstract Number: 1309 • ACR Convergence 2022
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University Hospital, Suwon, Republic of Korea
Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].